Tango Therapeutics Shares Surge 24% to New 52-Week High Following Collaboration with Erasca
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy TNGX?
Source: seekingalpha
- Clinical Trial Collaboration: Tango Therapeutics has entered into a clinical trial collaboration with Erasca to test the experimental cancer therapy ERAS-0015 alongside Tango's lead candidate vopimetostat, targeting patients with MTAP-deleted pancreatic and non-small cell lung cancers.
- Cost-Free Supply Agreement: Under the agreement, Erasca will supply ERAS-0015 at no cost for the Phase 1/2 study, significantly reducing Tango's research and development expenses while enhancing collaborative potential in cancer treatment.
- Financial Performance: For Q4 2025, Tango reported a net loss of $0.29 per share, exceeding consensus estimates by $0.03, but its revenue plummeted to zero from $5.4 million in the prior year, missing expectations by $0.5 million, indicating financial challenges ahead.
- Stock Price Reaction: Following the collaboration announcement, Tango's shares surged approximately 24%, reaching a new 52-week high, reflecting market optimism regarding the company's growth potential and likely attracting increased investor interest.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TNGX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TNGX
Wall Street analysts forecast TNGX stock price to rise
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 12.350
Low
12.00
Averages
13.67
High
15.00
Current: 12.350
Low
12.00
Averages
13.67
High
15.00
About TNGX
Tango Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering precision medicine for the treatment of cancer. The Company's novel small molecules are designed to be selectively active in cancer cells with specific genetic alterations, killing those cancer cells while sparing normal cells. It is also extending its target space beyond the classic, cell-autonomous effects of tumor suppressor gene loss. It is engaged in developing two methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors: TNG462 for non- central nervous system (CNS) cancers, including pancreatic and lung cancer, and TNG456, brain-penetrant PRMT5 inhibitor, for CNS cancers, including glioblastoma (GBM). Its TNG260 is a first-in-class Co-repressor of Repressor Element-1 Silencing Transcription (CoREST) inhibitor, which in preclinical studies reversed the immune evasion effect of STK11 loss-of-function mutations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tango Therapeutics Q4 Earnings Beat Expectations
- Earnings Highlights: Tango Therapeutics reported a Q4 GAAP EPS of -$0.29, beating expectations by $0.03, indicating some resilience in financial performance despite overall revenue shortfalls.
- Revenue Performance: The company reported $0M in revenue for Q4, missing the target by $0.5M, reflecting challenges in market penetration or product sales that could impact future cash inflows.
- Cash Reserves: As of December 31, 2025, Tango held $343.1 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into 2028, showcasing solid financial management.
- Market Outlook: Despite current financial shortcomings, Tango Therapeutics is actively participating in the 44th Annual J.P. Morgan Healthcare Conference, indicating efforts to bolster investor confidence and explore market opportunities.
See More
Boxer Capital Increases Stake in Tango Therapeutics
- Share Acquisition: Boxer Capital Management, LLC disclosed on February 17, 2026, that it purchased 1,104,734 shares of Tango Therapeutics, with an estimated transaction value of $9.52 million based on average closing prices from Q4 2025, indicating strong confidence in the biotech firm.
- Value Increase: This transaction raised the total value of Boxer Capital's position in Tango Therapeutics to $96.36 million, an increase of $14.28 million from the previous quarter, reflecting both the impact of share acquisition and stock price appreciation, thereby reinforcing its significance in the investment portfolio.
- Asset Management Proportion: Following the purchase, Tango Therapeutics now represents 21.09% of Boxer Capital's 13F reportable assets under management, making it one of the fund's key holdings and highlighting its strategic positioning in the biotech sector.
- Outstanding Market Performance: As of February 17, 2026, Tango Therapeutics shares were priced at $12.80, marking a 426.7% increase over the past year, significantly outperforming the S&P 500 by 406.3 percentage points, underscoring its potential and market recognition in the cancer therapeutics landscape.
See More
Tango Therapeutics Shares Surge 24% to New 52-Week High Following Collaboration with Erasca
- Clinical Trial Collaboration: Tango Therapeutics has entered into a clinical trial collaboration with Erasca to test the experimental cancer therapy ERAS-0015 alongside Tango's lead candidate vopimetostat, targeting patients with MTAP-deleted pancreatic and non-small cell lung cancers.
- Cost-Free Supply Agreement: Under the agreement, Erasca will supply ERAS-0015 at no cost for the Phase 1/2 study, significantly reducing Tango's research and development expenses while enhancing collaborative potential in cancer treatment.
- Financial Performance: For Q4 2025, Tango reported a net loss of $0.29 per share, exceeding consensus estimates by $0.03, but its revenue plummeted to zero from $5.4 million in the prior year, missing expectations by $0.5 million, indicating financial challenges ahead.
- Stock Price Reaction: Following the collaboration announcement, Tango's shares surged approximately 24%, reaching a new 52-week high, reflecting market optimism regarding the company's growth potential and likely attracting increased investor interest.
See More
Health Care Stocks Decline, NYSE Health Care Index Drops 2.3%
- Overall Decline in Health Care Stocks: On Thursday afternoon, health care stocks broadly fell, with the NYSE Health Care Index dropping 2.3%, reflecting market concerns about the sector's outlook, which could impact investor confidence and lead to capital outflows.
- Diminished Market Sentiment: The downward trend in the health care sector may be linked to overall economic uncertainty, as investors grow increasingly wary of potential policy changes and regulatory pressures, thereby affecting stock performance.
- Investor Reactions: In light of the decline in health care stocks, investors may reassess their portfolios, seeking more defensive asset allocations to mitigate potential market volatility and risks.
- Uncertain Industry Outlook: The short-term performance of the health care sector may be influenced by multiple factors, including policy changes and fluctuations in market demand, prompting investors to closely monitor developments to adjust their investment strategies.
See More
Erasca Partners with Tango for Clinical Trial of ERAS-0015
- Clinical Trial Collaboration: Erasca has entered into a clinical trial collaboration with Tango Therapeutics to evaluate the efficacy of Erasca's pan-RAS molecular glue, ERAS-0015, in combination with Tango's PRMT5 inhibitor, vopimetostat, targeting patients with MTAP-deleted RAS-mutant cancers, aiming to provide new treatment options.
- Drug Supply Agreement: Erasca will supply ERAS-0015 at no cost, while Tango will sponsor the trial, allowing both companies to retain commercial rights to their respective compounds, which not only reduces the clinical trial costs but also accelerates the development of new therapies.
- Early Clinical Data: ERAS-0015 has demonstrated favorable safety and tolerability in early clinical trials, achieving partial responses in patients with various tumor types at doses as low as 8 mg, indicating its potential in treating RAS-mutant cancers.
- Market Potential: The dual-targeting strategy of combining ERAS-0015 with a PRMT5 inhibitor may significantly enhance the suppression of MTAP-deleted tumor cells, potentially leading to deeper and more durable responses, thereby addressing the urgent market demand for new therapies.
See More
Boxer Capital Increases Stake in Tango Therapeutics
- Share Acquisition: Boxer Capital Management, LLC disclosed an increase of 1,104,734 shares in Tango Therapeutics on February 17, 2026, with an estimated transaction value of $9.52 million, reflecting strong confidence in the biotech firm.
- Increased Ownership: Following this acquisition, Boxer Capital's stake in Tango Therapeutics rose to 21.09%, indicating a significant emphasis on this biotech company within its investment portfolio.
- Outstanding Market Performance: As of February 17, 2026, Tango Therapeutics shares were priced at $12.80, marking a 426.7% increase over the past year, significantly outperforming the S&P 500 by 406.3 percentage points, suggesting optimistic market expectations for its future.
- Strategic Partnerships: Tango Therapeutics' collaboration with Gilead Sciences aims to develop and commercialize cancer therapies, further enhancing its competitiveness in the precision medicine sector and attracting investor interest.
See More
Tango Therapeutics Q4 Earnings Beat Expectations
- Earnings Highlights: Tango Therapeutics reported a Q4 GAAP EPS of -$0.29, beating expectations by $0.03, indicating some resilience in financial performance despite overall revenue shortfalls.
- Revenue Performance: The company reported $0M in revenue for Q4, missing the target by $0.5M, reflecting challenges in market penetration or product sales that could impact future cash inflows.
- Cash Reserves: As of December 31, 2025, Tango held $343.1 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into 2028, showcasing solid financial management.
- Market Outlook: Despite current financial shortcomings, Tango Therapeutics is actively participating in the 44th Annual J.P. Morgan Healthcare Conference, indicating efforts to bolster investor confidence and explore market opportunities.
See More
Boxer Capital Increases Stake in Tango Therapeutics
- Share Acquisition: Boxer Capital Management, LLC disclosed on February 17, 2026, that it purchased 1,104,734 shares of Tango Therapeutics, with an estimated transaction value of $9.52 million based on average closing prices from Q4 2025, indicating strong confidence in the biotech firm.
- Value Increase: This transaction raised the total value of Boxer Capital's position in Tango Therapeutics to $96.36 million, an increase of $14.28 million from the previous quarter, reflecting both the impact of share acquisition and stock price appreciation, thereby reinforcing its significance in the investment portfolio.
- Asset Management Proportion: Following the purchase, Tango Therapeutics now represents 21.09% of Boxer Capital's 13F reportable assets under management, making it one of the fund's key holdings and highlighting its strategic positioning in the biotech sector.
- Outstanding Market Performance: As of February 17, 2026, Tango Therapeutics shares were priced at $12.80, marking a 426.7% increase over the past year, significantly outperforming the S&P 500 by 406.3 percentage points, underscoring its potential and market recognition in the cancer therapeutics landscape.
See More
Tango Therapeutics Shares Surge 24% to New 52-Week High Following Collaboration with Erasca
- Clinical Trial Collaboration: Tango Therapeutics has entered into a clinical trial collaboration with Erasca to test the experimental cancer therapy ERAS-0015 alongside Tango's lead candidate vopimetostat, targeting patients with MTAP-deleted pancreatic and non-small cell lung cancers.
- Cost-Free Supply Agreement: Under the agreement, Erasca will supply ERAS-0015 at no cost for the Phase 1/2 study, significantly reducing Tango's research and development expenses while enhancing collaborative potential in cancer treatment.
- Financial Performance: For Q4 2025, Tango reported a net loss of $0.29 per share, exceeding consensus estimates by $0.03, but its revenue plummeted to zero from $5.4 million in the prior year, missing expectations by $0.5 million, indicating financial challenges ahead.
- Stock Price Reaction: Following the collaboration announcement, Tango's shares surged approximately 24%, reaching a new 52-week high, reflecting market optimism regarding the company's growth potential and likely attracting increased investor interest.
See More
Health Care Stocks Decline, NYSE Health Care Index Drops 2.3%
- Overall Decline in Health Care Stocks: On Thursday afternoon, health care stocks broadly fell, with the NYSE Health Care Index dropping 2.3%, reflecting market concerns about the sector's outlook, which could impact investor confidence and lead to capital outflows.
- Diminished Market Sentiment: The downward trend in the health care sector may be linked to overall economic uncertainty, as investors grow increasingly wary of potential policy changes and regulatory pressures, thereby affecting stock performance.
- Investor Reactions: In light of the decline in health care stocks, investors may reassess their portfolios, seeking more defensive asset allocations to mitigate potential market volatility and risks.
- Uncertain Industry Outlook: The short-term performance of the health care sector may be influenced by multiple factors, including policy changes and fluctuations in market demand, prompting investors to closely monitor developments to adjust their investment strategies.
See More
Erasca Partners with Tango for Clinical Trial of ERAS-0015
- Clinical Trial Collaboration: Erasca has entered into a clinical trial collaboration with Tango Therapeutics to evaluate the efficacy of Erasca's pan-RAS molecular glue, ERAS-0015, in combination with Tango's PRMT5 inhibitor, vopimetostat, targeting patients with MTAP-deleted RAS-mutant cancers, aiming to provide new treatment options.
- Drug Supply Agreement: Erasca will supply ERAS-0015 at no cost, while Tango will sponsor the trial, allowing both companies to retain commercial rights to their respective compounds, which not only reduces the clinical trial costs but also accelerates the development of new therapies.
- Early Clinical Data: ERAS-0015 has demonstrated favorable safety and tolerability in early clinical trials, achieving partial responses in patients with various tumor types at doses as low as 8 mg, indicating its potential in treating RAS-mutant cancers.
- Market Potential: The dual-targeting strategy of combining ERAS-0015 with a PRMT5 inhibitor may significantly enhance the suppression of MTAP-deleted tumor cells, potentially leading to deeper and more durable responses, thereby addressing the urgent market demand for new therapies.
See More
Boxer Capital Increases Stake in Tango Therapeutics
- Share Acquisition: Boxer Capital Management, LLC disclosed an increase of 1,104,734 shares in Tango Therapeutics on February 17, 2026, with an estimated transaction value of $9.52 million, reflecting strong confidence in the biotech firm.
- Increased Ownership: Following this acquisition, Boxer Capital's stake in Tango Therapeutics rose to 21.09%, indicating a significant emphasis on this biotech company within its investment portfolio.
- Outstanding Market Performance: As of February 17, 2026, Tango Therapeutics shares were priced at $12.80, marking a 426.7% increase over the past year, significantly outperforming the S&P 500 by 406.3 percentage points, suggesting optimistic market expectations for its future.
- Strategic Partnerships: Tango Therapeutics' collaboration with Gilead Sciences aims to develop and commercialize cancer therapies, further enhancing its competitiveness in the precision medicine sector and attracting investor interest.
See More
